Validation Data Gallery
|Positive WB detected in
|HeLa cells, Jurkat cells, K-562 cells, human placenta tissue, HT-1080 cells, A549 cells, NCI-H1299 cells, SKOV-3 cells, HUVEC cells, TF-1 cells
|Positive FC detected in
|Western Blot (WB)
|WB : 1:1000-1:8000
|Flow Cytometry (FC)
|FC : 0.20 ug per 10^6 cells in a 100 µl suspension
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
66304-1-Ig targets CD47 in WB, IF, FC, ELISA applications and shows reactivity with human samples.
|Host / Isotype
|Mouse / IgG2b
|CD47 fusion protein Ag14132
|Calculated molecular weight
|323 aa, 35 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Protein A purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
CD47, also known as integrin-associated protein (IAP), is a member of the immunoglobulin superfamily containing a five-pass transmembrane attachment. CD47 is heavily glycosylated and widely expressed by hematopoietic and nonhematopoietic cells. CD47 interacts with several membrane integrins and also acts a receptor for thrombospondin (THBS1). It is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. CD47 also functions as a ligand for signal regulatory protein-α (SIRPα). Upon binding CD47, SIRPα initiates a signaling cascade that results in the inhibition of phagocytosis.
J Control Release
Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers.
Bone-targeted erythrocyte-cancer hybrid membrane-camouflaged nanoparticles for enhancing photothermal and hypoxia-activated chemotherapy of bone invasion by OSCC.
Seedless preparation of Au nanorods by hydroquinone assistant and red blood cell membrane camouflage
J Cell Commun Signal
CD47 interactions with exportin-1 limit the targeting of m 7 G-modified RNAs to extracellular vesicles
J Cancer Res Clin Oncol
B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy
J Clin Lab Anal
MicroRNA-148a-3p inhibits cancer progression and is a novel screening biomarker for gastric cancer.